Key result
Ivabradine controls refractory tachycardia in thyroid storm within ~6 hours without causing hypotension.
Why the study?
Alternative heart rate control strategies are urgently needed in thyrotoxic crisis when beta-blockers are contraindicated or ineffective, and the use of ivabradine in thyrotoxic tachycardia has been described in only a few case reports.
Does ivabradine safely and effectively reduce heart rate in a patient with thyrotoxic crisis and refractory sinus tachycardia complicated by beta-blocker intolerance?
Case Report (n=1)
No
Does ivabradine safely and effectively reduce heart rate in a patient with thyrotoxic crisis and refractory sinus tachycardia complicated by beta-blocker intolerance?
Answers are grounded in this paper and cite their sources.
This case report demonstrates that oral ivabradine can rapidly and safely control refractory sinus tachycardia without inducing hypotension in a patient with thyroid storm and beta-blocker intolerance, serving as an effective bridge to definitive radioiodine therapy.
Thyrotoxic crisis is a rare but life-threatening endocrine emergency characterized by severe hyperadrenergic symptoms, including persistent sinus tachycardia, which can lead to hemodynamic instability and multiorgan failure. Beta-blockers are the mainstay of symptomatic treatment; however, in specific situations, such as hypotension, bronchospasm, or intolerance to beta-blockers, alternative strategies for controlling heart rate are urgently needed. Ivabradine, a selective inhibitor of the If current in the sinoatrial node, offers a promising option because it lowers heart rate without affecting myocardial contractility or systemic blood pressure. Although its theoretical benefits are recognized, the use of ivabradine in thyrotoxic tachycardia has been described in only a few case reports. We describe the case of a 39-year-old woman with alemtuzumab-induced Graves' disease who developed thyroid storm with refractory sinus tachycardia that was unresponsive to high-dose propranolol. Ivabradine was initiated, resulting in a significant reduction in heart rate within 24 hours, without causing hypotension or bradyarrhythmia. This stabilization allowed for definitive radioiodine treatment. Our case supports the emerging role of ivabradine as a safe and effective therapeutic option for the management of thyrotoxic crisis when beta-blockers are contraindicated or ineffective. A review of the literature reveals limited but growing evidence supporting its use in this setting. Further research and clinical awareness are necessary to better define ivabradine's role in the management of thyroid storm, especially in patients at high risk of beta-blocker intolerance or clinical decompensation.
No takes yet. Share an insight, caveat, or question.
Yassine et al. (2026) conducted a case report in Thyrotoxic crisis (thyroid storm) with refractory sinus tachycardia secondary to alemtuzumab-induced Graves' disease (n=1). Ivabradine was evaluated on Heart rate control. Ivabradine reduced refractory sinus tachycardia from >130 bpm to <100 bpm within 6 hours without causing hypotension in a patient with thyroid storm.
Synapse has enriched 10 related papers. Consider them for comparative context: